Send to

Choose Destination
Expert Opin Drug Discov. 2015 Jun;10(6):671-84. doi: 10.1517/17460441.2015.1041497. Epub 2015 Apr 30.

Preclinical discovery and development of maraviroc for the treatment of HIV.

Author information

University of Belgrade, Institute of Nuclear Sciences VINCA, Center for Multidisciplinary Research , P.O. Box 522, Belgrade , Serbia +381 11 3408154 ; + 381 11 7440100 ;



Maraviroc is a first-in-class antiretroviral (ARV) drug acting on a host cell target (CCR5), which blocks the entry of the HIV virus into the cell. Maraviroc is currently indicated for combination ARV treatment in adults infected only with CCR5-tropic HIV-1.


This drug discovery case history focuses on the key studies that led to the discovery and approval of maraviroc, as well as on post-launch clinical reports. The article is based on the data reported in published preclinical and clinical studies, conference posters and on drug package data.


The profound understanding of HIV's entry mechanisms has provided a strong biological rationale for targeting the chemokine receptor CCR5. The CCR5-antagonist mariviroc, with its unique mode of action and excellent safety profile, is an important therapeutic option for HIV patients. In general, the authors believe that targeting host factors is a useful approach for combating new and re-emerging transmissible diseases, as well as pathogens that easily become resistant to common antiviral drugs. Maraviroc, offering a potent and safe cellular receptor-mediated pharmacological response to HIV, has paved the way for the development of a new generation of host-targeting antivirals.


CCR5-receptor antagonist; HIV-1; antiretroviral therapy; entry inhibitor; maraviroc

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center